Matched‐related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: We report outcomes after myeloablative haematopoietic cell transplantation (HCT) from human leucocyte antigen (HLA)‐matched sibling donors in 67 patients with sickle cell disease transplanted between 1989 and 2002. The most common indications for transplantation were stroke and recurrent vaso‐occlusive crisis in 38% and 37% of patients respectively. The median age at transplantation was 10 years and 67% of patients had received >10 red blood cell transfusions before HCT. Twenty‐seven percent of patients had a poor performance score at transplantation. Ninety‐four percent received busulfan and cyclophosphamide‐containing conditioning regimens and bone marrow was the predominant source of donor cells. Most patients achieved haematopoietic recovery and no deaths occurred during the early post‐transplant period. Rates of acute and chronic graft‐versus‐host disease were 10% and 22% respectively. Sixty‐four of 67 patients are alive with 5‐year probabilities of disease‐free and overall survival of 85% and 97% respectively. Nine patients had graft failure with recovery of sickle erythropoiesis, eight of who had recurrent sickle‐related events. This report confirms and extends earlier reports that HCT from HLA‐matched related donors offers a very high survival rate, with few transplant‐related complications and the elimination of sickle‐related complications in the majority of patients who undergo this therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 2×
“The most frequent adverse events are painful vaso-occlusive crises (VOC) that often require hospitalisation (Platt et al, 1991, 1994).”
BackgroundCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546 · cited 1×
“The most frequent adverse events are painful vaso-occlusive crises (VOC) that often require hospitalisation (Platt et al, 1991, 1994).”
BackgroundPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa050460 · Cited by 635
Silent cerebral infarcts in sickle cell anemia: a risk factor analysis
Kinney, T. R., Sleeper, L. A., Wang, W. C., Zimmerman, R. A., Pegelow, C. H., Ohene-Frempong, K., Wethers, D. L., Bello, J. A., Vichinsky, E. P., Moser, F. G., et al. (1999) · PEDIATRICS · doi:10.1542/peds.103.3.640 · Cited by 309 · cited 1×
“…with increased cerebral arterial velocity in the large intracranial vessels are at high-risk for stroke, and that silent stroke affects at least 22% of patients and results in impaired cognitive functioning (Kinney et al, 1999; Schatz et al, 2001; Gladwin et al, 2004; Adams & Brambilla, 2005).”
Background
Cited by
Angelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M. D., Dalle, J.-H., Di Bartolomeo, P., de Heredia, C. D., Dickerhoff, R., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.099747 · Cited by 399
Locatelli, F., Kabbara, N., Ruggeri, A., Ghavamzadeh, A., Roberts, I., Li, C. K., Bernaudin, F., Vermylen, C., Dalle, J.-H., Stein, J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-489112 · Cited by 244
Self-citationHematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011825 · Cited by 166
Sickle cell disease: time for a closer look at treatment options?
Sheth, S., Licursi, M., & Bhatia, M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12413 · Cited by 57
Metadata
- Authors
- Panepinto, J. A., Walters, M. C., Carreras, J., Marsh, J., Bredeson, C. N., Gale, R. P., Hale, G. A., Horan, J., Hows, J. M., Klein, J. P., Pasquini, R., Roberts, I., Sullivan, K., Eapen, M., Ferster, A., & On behalf of the Non‐Malignant Marrow Disorders Working Committee, C. F. I. B. A. M. T. R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2007-05
- Volume
- 137
- Issue
- 5
- Pages
- 479-485
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2009398387
- Cited by
- 179
- References
- 6
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Matched‐related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. https://app.cochat.ai/papers/10.1111/j.1365-2141.2007.06592.x
- The paper
- Panepinto, J. A., Walters, M. C., Carreras, J., Marsh, J., Bredeson, C. N., Gale, R. P., Hale, G. A., Horan, J., Hows, J. M., Klein, J. P., Pasquini, R., Roberts, I., Sullivan, K., Eapen, M., Ferster, A., & On behalf of the Non‐Malignant Marrow Disorders Working Committee, C. F. I. B. A. M. T. R. (2007). Matched‐related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2007.06592.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.